Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Free Cash Flow: 2012-2024

Historic Free Cash Flow for Akebia Therapeutics (AKBA) over the last 13 years, with Dec 2024 value amounting to -$40.7 million.

  • Akebia Therapeutics' Free Cash Flow rose 518.52% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.2 million, marking a year-over-year increase of 183.50%. This contributed to the annual value of -$40.7 million for FY2024, which is 74.02% down from last year.
  • Akebia Therapeutics' Free Cash Flow amounted to -$40.7 million in FY2024, which was down 74.02% from -$23.4 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Free Cash Flow ranged from a high of -$23.4 million in FY2023 and a low of -$253.0 million during FY2021.
  • In the last 3 years, Akebia Therapeutics' Free Cash Flow had a median value of -$40.7 million in 2024 and averaged -$45.8 million.
  • Per our database at Business Quant, Akebia Therapeutics' Free Cash Flow slumped by 128.56% in 2021 and then spiked by 71.04% in 2022.
  • Akebia Therapeutics' Free Cash Flow (Yearly) stood at -$110.7 million in 2020, then slumped by 128.56% to -$253.0 million in 2021, then surged by 71.04% to -$73.3 million in 2022, then soared by 68.08% to -$23.4 million in 2023, then slumped by 74.02% to -$40.7 million in 2024.